The Public Weighs In On Medicare Drug Negotiations

The Public Weighs In On Medicare Drug Negotiations

KFF Health Tracking Poll: September 23 – October 4, 2021

Data Collected on SSRS Opinion Panel

Key Findings

  • With much attention on the public’s view on Medicare drug price negotiations, the latest KFF Tracking Poll finds large majorities support allowing the federal government to negotiate and this support holds steady even after the public is provided the arguments being presented by parties on both sides of the legislative debate (83% total, 95% of Democrats, 82% of independents, and 71% of Republicans).
  • Most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. prices were lower, drug companies would still make enough money to invest in the research needed to develop new drugs.” The results suggest that while hearing individual arguments may shift some views, the public still largely favors allowing Medicare drug negotiations when presented with the entirety of the public debate.